



PATHEON ADDS SOFTGEL CAPSULE CAPABILITY AT ITS CINCINNATI FACILITY

Names industry veteran Edgar Jaynes, Ph.D. to lead the unit.

RESEARCH TRIANGLE PARK, N.C., (April 13, 2010) – Patheon (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it is adding development and manufacturing softgel capability in its Cincinnati facility, providing the pharmaceutical industry a new contract provider for this popular drug delivery system. The company also announced that it has named Edgar Jaynes Ph.D. as its associate director of pharmaceutical development services. Dr. Jaynes comes to Patheon with broad industry experience in product development and manufacturing, particularly in soft gel technology.

“We are very excited to be able to offer our customers soft gel capabilities as they look to the contract development and manufacturing industry for additional choices for this manufacturing technology ,” said Wes Wheeler, Patheon’s CEO and President. “Adding soft gel equipment enhances our current liquid filled, hard gelatin capsule technology in Cincinnati and creates a more comprehensive service offering to our clients. We look forward to marketing this enhanced capability to our client base.”

Mr. Wheeler added, “I am also very pleased that Dr. Jaynes has agreed to join the organization. We look forward to his leadership and expertise and we are confident that he will be a key addition to our Cincinnati PDS operation.”

Dr. Jaynes, with over 20 years experience developing and assisting in the commercialization of a broad range of consumer and pharmaceutical products, comes to Patheon from Banner Pharmacaps, Inc., where he has been for the past 14 years. He holds a Ph.D. from the University of Wisconsin as well as a Bachelors of Science in Chemistry degree from West Virginia University. Dr. Jaynes has also been a postdoctoral research associate at the University of Pennsylvania and has served as a research associate at Case Western Reserve University.

ABOUT PATHEON

Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API. Patheon's integrated development and manufacturing network of 11 facilities, and eight development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.

Contact:

Mr. Wes Wheeler
President and Chief Executive Officer
Tel: (919) 226-3200
Email: wes.wheeler@patheon.com

Mr. Eric Evans
Chief Financial Officer
Tel: (919) 226-3204
Email: eric.evans@patheon.com

Ms. Wendy Wilson
Investor Relations
Tel: (919) 226-3313
Email: wendy.wilson@patheon.com

###